PHAXIAM Therapeutics S.A. (0QSS.L)

2.9246 -0.0687 (-2.30%) At close: 05:52PM BST

PHAXIAM Therapeutics S.A.

60 Avenue Rockefeller
Bâtiment Adénine
Lyon 69008
France
33 4 78 74 44 38
https://www.phaxiam.com

Sector(s): 
Industry: 
Full-time employees: 68

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eric Soyer Ph.D.	Deputy CEO, Deputy GM, CFO & COO	379.72k	N/A	1966
Dr. Jérôme Bailly Pharm.D.	Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person	247.91k	N/A	1979
Mr. Thibaut du Fayet	Chief Executive Officer	N/A	N/A	1968
Ms. Céline Breda	Chief Technology Officer	N/A	N/A	1971
Ms. Cindy Fevre	Chief Scientific Officer	N/A	N/A	N/A
Naomi Eichenbaum	Director Investor Relations	N/A	N/A	N/A
Ms. Anne-Cécile Fumey	Vice President of Human Resources	N/A	N/A	1976
Ms. Karine Charton Ph.D.	Chief Business Officer	N/A	N/A	N/A
Dr. Pascal Birman M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Frederique Vieville	Chief Regulatory Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Corporate governance

PHAXIAM Therapeutics S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.